Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Gregory B. Lesinski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8787-7678; OpenAlex author ID A5032094154; NIH RePORTER profile ID 9239753. Sources: OpenAlex.

Their work

Papers
40 (first author 1, last author 18)
Trials
0
Grants
7
Labs led
3
Collaborators
113
Papers, trials and grants by year

2013: 4 papers · 2014: 2 papers · 2015: 5 papers · 2016: 2 papers · 2017: 2 papers, 1 grant · 2018: 5 papers · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers, 1 grant · 2022: 3 papers · 2023: 1 paper, 2 grants · 2024: 3 papers, 1 grant · 2025: 1 paper · 2026: 5 papers, 2 grants

Papers 40

  1. A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Last author DOI 10.1016/j.canlet.2025.218233↗
  2. Interleukin-6: The Unexpected Opponent to Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2026.101799↗
  3. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-25-1697↗
  4. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-26-0614↗
  5. MetScore and classical–basal subtype intersect to define chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.09.14.751470↗
  6. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  7. Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.omton.2024.200868↗
  8. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. Last author DOI 10.1136/jitc-2023-008086↗
  9. VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3628↗
  10. Top advances of the year: Pancreatic cancer. First author DOI 10.1002/cncr.35031↗
  11. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-022-34242-4↗
  12. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model. Co-author DOI 10.1186/s12985-022-01757-7↗
  13. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.26508/lsa.202201460↗
  14. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Last author DOI 10.1007/s10555-021-09988-w↗
  15. Braking the cell's cycle and invigorating T-cell immunity against pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321497↗
  16. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-19-0911↗
  17. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. Last author DOI 10.1136/jitc-2020-001100↗
  18. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Last author DOI 10.1172/jci.insight.130362↗
  19. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Co-author DOI 10.1002/ijc.32227↗
  20. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  21. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Co-author DOI 10.1002/jcsm.12251↗
  22. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  23. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Last author DOI 10.1136/gutjnl-2016-311585↗
  24. Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells. Co-author DOI 10.21037/apc.2018.09.03↗
  25. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Last author DOI 10.3389/fimmu.2018.02166↗
  26. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Co-author DOI 10.1002/cncr.30944↗
  27. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1986↗
  28. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  29. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-1732↗
  30. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Co-author DOI 10.1007/s00262-014-1618-8↗
  31. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-015-1679-3↗
  32. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Last author DOI 10.1186/2051-1426-3-s2-p366↗
  33. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients Last author DOI 10.1186/2051-1426-3-s2-p85↗
  34. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Last author DOI 10.18632/oncotarget.6332↗
  35. A mathematical model for pancreatic cancer growth and treatments. Co-author DOI 10.1016/j.jtbi.2014.02.028↗
  36. BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer Last author DOI 10.1186/2051-1426-2-s3-p186↗
  37. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2013.04.061↗
  38. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Last author DOI 10.1158/0008-5472.can-12-4601↗
  39. Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients Last author DOI 10.1186/2051-1426-1-s1-p163↗
  40. Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment. Last author DOI 10.4161/onci.24891↗

Grants 7

  1. Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer R01CA287866↗
  2. Targeting VIP–VPAC Signaling to Reverse Immune Exclusion and Enhance Immunotherapy Response in Pancreatic Cancer R01CA314282↗
  3. Development of a PET CCR2 Imaging Agent to Profile PDAC Microenvironment R21CA286283↗
  4. Targeting immune stroma interactions in pancreatic cancer R01CA228406↗
  5. Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade R21CA266088↗
  6. Enhancing immune therapy in pancreatic cancer by targeting IL-6 R01CA208253↗
  7. Stromal IL -6/Jak-STAT Signaling and Pancreatitis R21AI124687↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 12 shared papers, 2 shared grants, 2016–2026 · strength 3.31
  2. Edmund K Waller · 3 shared papers, 2 shared grants, 2018–2026 · strength 2.69
  3. Chrystal M Paulos · 3 shared papers, 1 shared grant, 2024–2026 · strength 1.67
  4. Cameron J. Herting · 5 shared papers, 2021–2026 · strength 1.08
  5. Shishir Kumar Maithel · 5 shared papers, 2020–2026 · strength 0.99
  6. Olatunji Boladale Alese · 4 shared papers, 2025–2026 · strength 0.95
  7. Mark Myron Goodman · 1 shared grant, 2024 · strength 0.91
  8. Matthew R. Farren · 10 shared papers, 2015–2026 · strength 0.86
  9. Michael B. Ware · 5 shared papers, 2020–2026 · strength 0.76
  10. Ganji Purnachandra Nagaraju · 5 shared papers, 2017–2026 · strength 0.74
  11. Juan Manuel Sarmiento · 4 shared papers, 2020–2026 · strength 0.69
  12. Thomas A. Mace · 14 shared papers, 2013–2019 · strength 0.68
  13. Natalie K. Horvat · 3 shared papers, 2024–2026 · strength 0.67
  14. Tanios Bekaii‐Saab · 13 shared papers, 2013–2019 · strength 0.61
  15. Michael C. Ostrowski · 5 shared papers, 1 shared grant, 2013–2022 · strength 0.60
  16. Richard A. Moffitt · 2 shared papers, 2024–2026 · strength 0.49
  17. Mark Bloomston · 10 shared papers, 2013–2019 · strength 0.48
  18. Emily R. Greene · 2 shared papers, 2026 · strength 0.47
  19. Maria Diab · 2 shared papers, 2026 · strength 0.47
  20. Alyssa M. Krasinskas · 2 shared papers, 2020–2026 · strength 0.32
  21. Sruthi Ravindranathan · 2 shared papers, 2022–2024 · strength 0.32
  22. Tenzin Passang · 2 shared papers, 2022–2024 · strength 0.32
  23. Lily Yang · 2 shared papers, 2017–2024 · strength 0.31
  24. E. Warren · 1 shared paper, 2023 · strength 0.31
  25. Mehmet Akce · 2 shared papers, 2018–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.